Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000992871 | SCV001145438 | likely benign | not provided | 2018-09-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000992871 | SCV002311144 | likely benign | not provided | 2024-10-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002550647 | SCV003676923 | uncertain significance | Inborn genetic diseases | 2021-06-15 | criteria provided, single submitter | clinical testing | The c.6572C>T (p.P2191L) alteration is located in exon 34 (coding exon 33) of the SPTBN2 gene. This alteration results from a C to T substitution at nucleotide position 6572, causing the proline (P) at amino acid position 2191 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000992871 | SCV005882433 | uncertain significance | not provided | 2024-09-05 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign in association with an SPTBN2-related disorder to our knowledge; This variant is associated with the following publications: (PMID: 26740555, 28719003) |